Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $2.77 in the prior trading day, Outlook Therapeutics Inc (NASDAQ: OTLK) closed at $2.63, down -5.05%. In other words, the price has decreased by -$5.05 from its previous closing price. On the day, 2.34 million shares were traded. OTLK stock price reached its highest trading level at $2.95 during the session, while it also had its lowest trading level at $2.62.
Ratios:
Our goal is to gain a better understanding of OTLK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 0.67.
On March 27, 2024, BTIG Research Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Chardan Capital Markets Upgraded its Neutral to Buy on February 15, 2024, while the target price for the stock was maintained at $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 26 ’24 when KENYON LAWRENCE A bought 5,000 shares for $5.69 per share. The transaction valued at 28,446 led to the insider holds 5,946 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 112705232 and an Enterprise Value of 142620256. For the stock, the TTM Price-to-Sale (P/S) ratio is 77.37. Its current Enterprise Value per Revenue stands at 94.744 whereas that against EBITDA is -1.967.
Stock Price History:
The Beta on a monthly basis for OTLK is 0.54, which has changed by -0.6382394 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, OTLK has reached a high of $8.32, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is 33.18%, while the 200-Day Moving Average is calculated to be 22.65%.
Shares Statistics:
The stock has traded on average 1.06M shares per day over the past 3-months and 2153950 shares per day over the last 10 days, according to various share statistics. A total of 43.48M shares are outstanding, with a floating share count of 27.40M. Insiders hold about 38.31% of the company’s shares, while institutions hold 22.50% stake in the company. Shares short for OTLK as of 1753920000 were 2349479 with a Short Ratio of 2.22, compared to 1751241600 on 2190871. Therefore, it implies a Short% of Shares Outstanding of 2349479 and a Short% of Float of 6.710000000000001.
Earnings Estimates
The current assessment of Outlook Therapeutics Inc (OTLK) involves the perspectives of 3.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.42 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.72 and -$1.96 for the fiscal current year, implying an average EPS of -$1.83. EPS for the following year is -$1.08, with 3.0 analysts recommending between -$0.52 and -$1.55.
Revenue Estimates
For the next quarter, 3 analysts are estimating revenue of $5M. There is a high estimate of $5M for the next quarter, whereas the lowest estimate is $5M.
Based on 5 analysts’ estimates, the company’s revenue will be $34.59M in the next fiscal year. The high estimate is $51M and the low estimate is $17.1M.
